Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?

Checkpoint inhibitors were a major breakthrough in the field of oncology. In September 2014, based on the KEYNOTE-001 study, the Food and Drug Administration (FDA) approved pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, for advanced or unresectable melanoma. Up until now, seven P...

Cijeli opis

Bibliografski detalji

Glavni autori:	Laura Jimbu, Oana Mesaros, Cristian Popescu, Alexandra Neaga, Iulia Berceanu, Delia Dima, Mihaela Gaman, Mihnea Zdrenghea
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2021-03-01
Serija:	Pharmaceuticals
Teme:	acute myeloid leukemia checkpoint inhibitors immune system cancer
Online pristup:	https://www.mdpi.com/1424-8247/14/4/288
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!